Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0032580
Disease: Adenomatous Polyposis Coli
Adenomatous Polyposis Coli 		0.010 AlteredExpression disease BEFREE Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients. 28306719 2017
CUI: C2751492
Disease: AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED
AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED 		0.010 AlteredExpression disease BEFREE Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients. 28306719 2017
CUI: C0033036
Disease: Atrial Premature Complexes
Atrial Premature Complexes 		0.010 AlteredExpression disease BEFREE Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients. 28306719 2017
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms 		0.010 Biomarker group BEFREE Our data strongly support further development of CPA-7-derived compounds with increased permeability to enhance their efficacy in primary and metastatic brain tumors. 24696041 2014
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.010 GeneticVariation disease BEFREE These include four loci that were associated (unadjusted P<0.05) with breast cancer (GTF2H2, ZNF385B, NAALADL2 and PSG5), and two loci associated with ovarian cancer (CYP2A7 and OR2A1). 28145423 2017
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.010 AlteredExpression phenotype BEFREE These data signify that CYP2A and CYP1A isoforms expressed in the target urothelium bioactivate 4-ABP and AαC, respectively, and may be a critical feature of aromatic amine-induced urinary bladder carcinogenesis. 31203411 2019
CUI: C4721610
Disease: Carcinoma, Ovarian Epithelial
Carcinoma, Ovarian Epithelial 		0.010 GeneticVariation disease BEFREE These include four loci that were associated (unadjusted P<0.05) with breast cancer (GTF2H2, ZNF385B, NAALADL2 and PSG5), and two loci associated with ovarian cancer (CYP2A7 and OR2A1). 28145423 2017
CUI: C4277682
Disease: Chemical and Drug Induced Liver Injury
Chemical and Drug Induced Liver Injury 		0.200 Therapeutic disease CTD_mouse Cytochrome P450 2A5 and bilirubin: mechanisms of gene regulation and cytoprotection. 23628428 2013
CUI: C0596321
Disease: Chemical Carcinogenesis
Chemical Carcinogenesis 		0.010 Biomarker phenotype BEFREE The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. 7581481 1995
CUI: C4279912
Disease: Chemically-Induced Liver Toxicity
Chemically-Induced Liver Toxicity 		0.200 Therapeutic disease CTD_mouse Cytochrome P450 2A5 and bilirubin: mechanisms of gene regulation and cytoprotection. 23628428 2013
CUI: C0024117
Disease: Chronic Obstructive Airway Disease
Chronic Obstructive Airway Disease 		0.010 GeneticVariation disease BEFREE Previously reported associations on chromosome 19 showed suggestive and directionally consistent associations among common variants (RAB4, CYP2A7, and CYP2B6) and for rare variants (CYP2A7) among COPDGene NHW subjects. 29767774 2019
CUI: C0013170
Disease: Drug habituation
Drug habituation 		0.010 Biomarker phenotype BEFREE However, the combination of gastrointestinal digestion and habituation on the fruit resulted in a significant reduction of CPA-7 populations (by 2 log<sub>10</sub> more after 7d of incubation than on inoculation day) as well as in the decrease of its adhesiveness (by 0.8 log<sub>10</sub>) and invasiveness (to undetectable levels). 28964998 2017
CUI: C3658290
Disease: Drug-Induced Acute Liver Injury
Drug-Induced Acute Liver Injury 		0.200 Therapeutic disease CTD_mouse Cytochrome P450 2A5 and bilirubin: mechanisms of gene regulation and cytoprotection. 23628428 2013
CUI: C0860207
Disease: Drug-Induced Liver Disease
Drug-Induced Liver Disease 		0.200 Therapeutic phenotype CTD_mouse Cytochrome P450 2A5 and bilirubin: mechanisms of gene regulation and cytoprotection. 23628428 2013
CUI: C0086404
Disease: Experimental Hepatoma
Experimental Hepatoma 		0.200 Biomarker disease CTD_mouse Expression profiling and identification of novel genes in hepatocellular carcinomas. 11420682 2001
CUI: C1611743
Disease: Familial (FPAH)
Familial (FPAH) 		0.010 GeneticVariation disease BEFREE Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients. 28306719 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.010 Biomarker disease BEFREE To this end, we evaluated the STAT3-inhibitory activities of three compounds (CPA-7 [trichloronitritodiammineplatinum(IV)], WP1066 [(S,E)-3-(6-bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide, C17H14BrN3O], and ML116 [4-benzyl-1-{thieno[2,3-d]pyrimidin-4-yl}piperidine, C18H19N3S]) in cultured rodent and human glioma cells, including GBM cancer stem cells. 24696041 2014
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.010 Biomarker disease BEFREE To this end, we evaluated the STAT3-inhibitory activities of three compounds (CPA-7 [trichloronitritodiammineplatinum(IV)], WP1066 [(S,E)-3-(6-bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide, C17H14BrN3O], and ML116 [4-benzyl-1-{thieno[2,3-d]pyrimidin-4-yl}piperidine, C18H19N3S]) in cultured rodent and human glioma cells, including GBM cancer stem cells. 24696041 2014
CUI: C0018834
Disease: Heartburn
Heartburn 		0.010 Biomarker phenotype BEFREE The fruit quality (total soluble solids content and titratable acidity) was not negatively affected by CPA-7. 30166146 2018
CUI: C0019196
Disease: Hepatitis C
Hepatitis C 		0.010 Biomarker disease BEFREE We found that the naive CTL repertoire of both groups contains cross-reactive CTLs inducible by the HCV peptide recognizing both CYP2A6 and CYP2A7 peptides as well as endogenously processed CYP2A6 protein. 10432280 1999
CUI: C1262760
Disease: Hepatitis, Drug-Induced
Hepatitis, Drug-Induced 		0.200 Therapeutic disease CTD_mouse Cytochrome P450 2A5 and bilirubin: mechanisms of gene regulation and cytoprotection. 23628428 2013
CUI: C0019193
Disease: Hepatitis, Toxic
Hepatitis, Toxic 		0.200 Therapeutic disease CTD_mouse Cytochrome P450 2A5 and bilirubin: mechanisms of gene regulation and cytoprotection. 23628428 2013
CUI: C0019207
Disease: Hepatoma, Morris
Hepatoma, Morris 		0.200 Biomarker disease CTD_mouse Expression profiling and identification of novel genes in hepatocellular carcinomas. 11420682 2001
CUI: C0019208
Disease: Hepatoma, Novikoff
Hepatoma, Novikoff 		0.200 Biomarker disease CTD_mouse Expression profiling and identification of novel genes in hepatocellular carcinomas. 11420682 2001
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.010 Biomarker disease BEFREE In summary, our results confirmed for the first time that a four-CYP gene (CYP1A2, CYP2E1, CYP2A7, and PTGIS) signature is associated with fast-growing HCC, and CYP2C8 is associated with patient survival. 30971588 2020